Orbit Genomics Revenue and Competitors

Since the first sequencing of the human genome in 2003, tremendous gains have been made in understanding hereditary cancer syndromes, with over 50 having been identified. Genetic tests to assess a person’s inherited risk of developing certain cancers are abundant. However, these tests are not clinically actionable for most healthy people. Genetic mutations measure population risk, not individual risk. Genetic mutations (SNPs) identify increased disease risk, however their presence doesn’t guarantee disease will occur, and their absence doesn’t guarantee disease will not occur. Complex diseases are caused by a combination of genetic mutations and environmental factors, including lifestyle. Orbit Genomics’ proprietary OrbiSeq technology platform analyzes novel genomic markers called microsatellites that uniquely reflect both inherited risk and risk acquired due to lifestyle and environmental exposures. Microsatellites are much more responsive than SNPs, measuring individual disease risk. They are your DNA’s early warning system. Our aim is to accelerate precision medicine by developing clinically actionable tests.